Literature DB >> 12578117

Impaired production of interferon-gamma and tumor necrosis factor-alpha but not of interleukin 10 in whole blood of patients with sepsis.

Otelo Rigato1, Reinaldo Salomao.   

Abstract

It has been demonstrated that lipopolysaccharide (LPS)-induced cytokine response in patients with sepsis differ from the normal host, yet this has not been controlled for the presence of underlying disease. We studied the ability of LPS and killed gram-negative bacteria (GNB) to induce tumor necrosis factor (TNF)-alpha and interleukin (IL) 10, and of phytohemagglutinin (PHA) to induce interferon (IFN)-gamma, in whole blood from patients with sepsis (SP, n = 20), patients with matched underlying disease and without sepsis (control patients, n = 20), and healthy volunteers (HV, n = 20). LPS-induced TNF-alpha production was lower in SP (median = 638 pg/mL) compared with control patients (4060 pg/mL; P= 0.003), and control patients production was lower compared with HV (5329 pg/mL; P < 0.001). Pseudomonas aeruginosa-induced TNF-alpha production was lower in SP (1443 pg/mL) than in control patients (7319 pg/mL; P < 0.05), and was not different between control patients and HV (6612 pg/mL; P = 0.6). IFNy production was lower in SP (948 pg/mL) compared with control patients (5516 pg/mL; P < 0.001), and the control patients production was lower compared with HV (11,282 pg/mL; P < 0.001). IL-10 production was not different among the three groups. Down-regulation of TNF-alpha production in patients with sepsis, although not restricted to them, was more pronounced with LPS than with GNB. Although the presence of underlying disease may be involved in the regulatory mechanisms of host response, the use of controls with matched underlying diseases provides strong evidence for the septic condition in the down-regulation of inflammatory response in patients with sepsis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12578117     DOI: 10.1097/00024382-200302000-00004

Source DB:  PubMed          Journal:  Shock        ISSN: 1073-2322            Impact factor:   3.454


  33 in total

Review 1.  Advances in the management of sepsis and the understanding of key immunologic defects.

Authors:  Lee P Skrupky; Paul W Kerby; Richard S Hotchkiss
Journal:  Anesthesiology       Date:  2011-12       Impact factor: 7.892

Review 2.  [Relaparotomy in secondary peritonitis Planned relaparotomy or relaparotomy on demand?].

Authors:  B Lamme; C W Mahler; J W O van Till; O van Ruler; D J Gouma; M A Boermeester
Journal:  Chirurg       Date:  2005-09       Impact factor: 0.955

3.  Immunosuppression in patients who die of sepsis and multiple organ failure.

Authors:  Jonathan S Boomer; Kathleen To; Kathy C Chang; Osamu Takasu; Dale F Osborne; Andrew H Walton; Traci L Bricker; Stephen D Jarman; Daniel Kreisel; Alexander S Krupnick; Anil Srivastava; Paul E Swanson; Jonathan M Green; Richard S Hotchkiss
Journal:  JAMA       Date:  2011-12-21       Impact factor: 56.272

Review 4.  Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach.

Authors:  Richard S Hotchkiss; Guillaume Monneret; Didier Payen
Journal:  Lancet Infect Dis       Date:  2013-03       Impact factor: 25.071

Review 5.  Immunotherapy: A promising approach to reverse sepsis-induced immunosuppression.

Authors:  Naeem K Patil; Julia K Bohannon; Edward R Sherwood
Journal:  Pharmacol Res       Date:  2016-07-25       Impact factor: 7.658

6.  T helper type 2-polarized invariant natural killer T cells reduce disease severity in acute intra-abdominal sepsis.

Authors:  R V Anantha; D M Mazzuca; S X Xu; S A Porcelli; D D Fraser; C M Martin; I Welch; T Mele; S M M Haeryfar; J K McCormick
Journal:  Clin Exp Immunol       Date:  2014-11       Impact factor: 4.330

Review 7.  Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy.

Authors:  Richard S Hotchkiss; Guillaume Monneret; Didier Payen
Journal:  Nat Rev Immunol       Date:  2013-11-15       Impact factor: 53.106

Review 8.  Pathophysiology of sepsis.

Authors:  Daniel G Remick
Journal:  Am J Pathol       Date:  2007-05       Impact factor: 4.307

Review 9.  Monitoring immune dysfunctions in the septic patient: a new skin for the old ceremony.

Authors:  Guillaume Monneret; Fabienne Venet; Alexandre Pachot; Alain Lepape
Journal:  Mol Med       Date:  2008 Jan-Feb       Impact factor: 6.354

10.  Frontline Science: Defects in immune function in patients with sepsis are associated with PD-1 or PD-L1 expression and can be restored by antibodies targeting PD-1 or PD-L1.

Authors:  Andriani C Patera; Anne M Drewry; Katherine Chang; Evan R Beiter; Dale Osborne; Richard S Hotchkiss
Journal:  J Leukoc Biol       Date:  2016-09-26       Impact factor: 4.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.